SCHEMBL4366283

SCHEMBL4366283

C=C(CC)Oc1ccc(C(=O)O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.53
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
HTT P42858 2/20 0.49
PLA2G4B P0C869 3/20 0.49
KMT2A Q03164 2/20 0.49
TP53 P04637 1/20 0.49
TSHR P16473 1/20 0.49
ELANE P08246 1/20 0.49
ESR1 P03372 1/20 0.49
RECQL P46063 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HIF1A Q16665 1/20 0.49
RXRA P19793 1/20 0.47
RXRB P28702 1/20 0.47
ALDH1A1 P00352 1/20 0.47
PKM P14618 1/20 0.46
POLB P06746 1/20 0.45
APEX1 P27695 1/20 0.45
TDP1 Q9NUW8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9175269 0.83 ALDH1A1 (0.53) HSD17B10CA1CA2HTTPLA2G4B
SCHEMBL5690655 0.81 KMT2A (0.72) HSD17B10CA1CA2HTTPLA2G4B
SCHEMBL638468 0.80 PLA2G4B (0.56) HTTPLA2G4BTP53TSHRALDH1A1
SCHEMBL8003544 0.79 HSD17B10 (0.63) HSD17B10CA1CA2HTTKMT2A
SCHEMBL9447460 0.78 ELANE (0.43) TSHRELANERECQLSMN1; SMN2ALDH1A1
Propane SCHEMBL28675522 0.77 HSD17B10 (0.79) HSD17B10CA1CA2PLA2G4BKMT2A
SCHEMBL7029995 0.76 HSD17B10 (0.51) HSD17B10CA1CA2HTTPLA2G4B
SCHEMBL19034668 0.76 LMNA (0.48) CA1CA2KMT2AESR1RECQL
SCHEMBL19382921 0.76 LMNA (0.58)
SCHEMBL346685 0.76 ELANE (0.72) HSD17B10CA1CA2HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1908466-B1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME DAIICHI SANKYO CO LTD (JP) 2014-02-19 EP disclosed
US-8344029-B2 Substituted propanamide derivative and pharmaceutical composition containing the same DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-01 US disclosed
US-20090292024-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-11-26 US disclosed
EP-1908466-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME Daiichi Sankyo Company, Limited (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090292024-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME PTMS, C1S, ACP3 HSD17B10 483/4885CA1 866/4885CA2 364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.